secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001599298-25-000034
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics reports preliminary cash ≥$410M as of Dec 31, 2024
----------------------------------------------------------------------

- Preliminary unaudited cash, cash equivalents, and short-term investments at least $410M.
- Includes repayment of $31.8M related party loan (principal + interest) previously outstanding.
- Amount is preliminary and subject to completion of year-end financial closing procedures.
- Company presenting at J.P. Morgan Healthcare Conference on January 13, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000034/0001599298-25-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000034/smmt-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001599298-25-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer